Filtered By:
Cancer: Prostate Cancer
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 637 results found since Jan 2013.
Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
This article also emphasized the recent advances in the field of medicinal chemistry of prostate cancer agents.PMID:37694781 | DOI:10.2174/1389557523666230911141339
Source: Mini Reviews in Medicinal Chemistry - September 11, 2023 Category: Chemistry Authors: Manish Chaudhary Shubham Kumar Paranjeet Kaur Sanjeev Kumar Sahu Amit Mittal Source Type: research
Growing Deficit in New Cancer Diagnoses 2 Years Into the COVID-19 Pandemic: A National Multicenter Study
CONCLUSION: Disruptions in new diagnoses of four common cancers (prostate, lung, bladder, and colorectal) seen early in the COVID-19 pandemic have persisted for 2 years. Although reductions improved from the early pandemic, new reductions during the Delta and Omicron waves demonstrate the continued impact of the COVID-19 pandemic on cancer care.PMID:37695458 | DOI:10.1245/s10434-023-14217-5
Source: Ann Oncol - September 11, 2023 Category: Cancer & Oncology Authors: Brian R Englum Shalini Sahoo Minerva Mayorga-Carlin Hilary Hayssen Tariq Siddiqui Douglas J Turner John D Sorkin Brajesh K Lal Source Type: research
Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
This article also emphasized the recent advances in the field of medicinal chemistry of prostate cancer agents.PMID:37694781 | DOI:10.2174/1389557523666230911141339
Source: Mini Reviews in Medicinal Chemistry - September 11, 2023 Category: Chemistry Authors: Manish Chaudhary Shubham Kumar Paranjeet Kaur Sanjeev Kumar Sahu Amit Mittal Source Type: research
Growing Deficit in New Cancer Diagnoses 2 Years Into the COVID-19 Pandemic: A National Multicenter Study
CONCLUSION: Disruptions in new diagnoses of four common cancers (prostate, lung, bladder, and colorectal) seen early in the COVID-19 pandemic have persisted for 2 years. Although reductions improved from the early pandemic, new reductions during the Delta and Omicron waves demonstrate the continued impact of the COVID-19 pandemic on cancer care.PMID:37695458 | DOI:10.1245/s10434-023-14217-5
Source: Ann Oncol - September 11, 2023 Category: Cancer & Oncology Authors: Brian R Englum Shalini Sahoo Minerva Mayorga-Carlin Hilary Hayssen Tariq Siddiqui Douglas J Turner John D Sorkin Brajesh K Lal Source Type: research
Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
This article also emphasized the recent advances in the field of medicinal chemistry of prostate cancer agents.PMID:37694781 | DOI:10.2174/1389557523666230911141339
Source: Mini Reviews in Medicinal Chemistry - September 11, 2023 Category: Chemistry Authors: Manish Chaudhary Shubham Kumar Paranjeet Kaur Sanjeev Kumar Sahu Amit Mittal Source Type: research
Advances in bio-immunotherapy for castration-resistant prostate cancer
J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05152-9. Online ahead of print.ABSTRACTProstate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change...
Source: Clinical Prostate Cancer - July 17, 2023 Category: Cancer & Oncology Authors: Canling Lin Yonghui Chen Liji Shi Huarong Lin Hongmei Xia Weihua Yin Source Type: research
Prostate-specific antigen level association with COVID-19 infection and vaccination
CONCLUSION: SARS-CoV-2 infection and vaccinations are associated with a slight increase in PSA, with the third anti-COVID vaccine dose having a more prominent impact, but its clinical significance is unknown yet. Any significant increase in PSA must be investigated and cannot be dismissed as secondary to SARS-CoV-2 infection or vaccination.PMID:37270370 | PMC:PMC10159928 | DOI:10.1016/j.clgc.2023.05.001
Source: Clinical Prostate Cancer - June 3, 2023 Category: Cancer & Oncology Authors: Michael Frumer Shachar Moshe Aharony Ohad Shoshany Daniel Kedar Jack Baniel Shay Golan Source Type: research
The chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers
Curr Drug Deliv. 2023 May 12. doi: 10.2174/1567201820666230512122825. Online ahead of print.ABSTRACTThe lymphatic system (LS) plays a crucial role in fluid balance, transportation of macromolecules, and immune response. Moreover, LS is a channel for microbial invasion and cancer metastasis. Particularly, solid tumors, including lung, breast, melanoma, and prostate cancers, are metastasized across highways of LS. Subsequently, the fabrication of chimeric lymphatic drug delivery systems (LDDS) is a promising strategy to fight cancer metastasis and control microbial pandemics. In this regard, LDDS, in terms of PEG-nanoscaled ...
Source: Current Drug Delivery - May 15, 2023 Category: Drugs & Pharmacology Authors: Abdelrahman Y Sherif Gamaleldin I Harisa Fars K Alanazi Source Type: research
Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy
Am J Clin Exp Urol. 2023 Apr 15;11(2):79-102. eCollection 2023.ABSTRACTAlthough PSA testing is widely used in prostate cancer diagnosis, it remains an imperfect assay due to its lack of accuracy. While several urine or tissue-based gene expression assays are available to identify patients with higher risk of adverse disease and to aid in deciding treatment options, there is still a critical need for reliable biomarkers to monitor disease progression and treatment response. Autoantibodies (AAbs) produced by the humoral immune response against tumor associated antigens offer an attractive alternative, as they target a wide v...
Source: Clinical Prostate Cancer - May 11, 2023 Category: Cancer & Oncology Authors: Rahul Jayakrishnan Cara Schafer Shyh-Han Tan Source Type: research
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer
CONCLUSION: The combination of flutamide+PROSTVAC did not improve outcomes in men with nmCRPC compared with flutamide alone. (ClinicalTrials.gov Identifier: NCT00450463).PMID:37134294 | DOI:10.1093/oncolo/oyad058
Source: The Oncologist - May 3, 2023 Category: Cancer & Oncology Authors: Ravi A Madan Marijo Bilusic Mark N Stein Renee N Donahue Philip M Arlen Fatima Karzai Elizabeth Plimack Yu-Ning Wong Daniel M Geynisman Matthew Zibelman Tina Mayer Julius Strauss Gang Chen Myrna Rauckhorst Sheri McMahon Anna Couvillon Seth Steinberg Willi Source Type: research
Plant-derived PAP proteins fused to immunoglobulin A and M Fc domains induce anti-prostate cancer immune response in mice
In this study, recombinant Fc-fused Prostate acid phosphatase (PAP) proteins were produced in transgenic plants. PAP was fused to immunoglobulin (Ig) A and M Fc domain (PAP-IgA Fc and PAP-IgM Fc), which were tagged to the ER retention sequence KDEL to generate PAP-IgA FcK and PAP-IgM FcK. Agrobacterium-meditated transformation was performed to produce transgenic tobacco plants expressing four recombinant proteins. Genomic PCR and RT-PCR analyses confirmed the transgene insertion and mRNA transcription of PAP-IgA Fc, PAP-IgM Fc, PAP-IgA FcK, and PAP-IgM FcK in tobacco plant leaves. Western blot confirmed the expression of P...
Source: BMB Reports - April 10, 2023 Category: Biochemistry Authors: Yang Joo Kang Deuk-Su Kim Seyoung Kim Young-Jin Seo Kisung Ko Source Type: research
